The strategic absorption of ImmunoGen's former operations into a global oncology framework is now complete. Investor attention has consequently shifted toward t ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
A new HIC–MS method using ammonium tartrate improves ADC characterization, enabling efficient drug-to-antibody ratio analysis without complex workflows. A proteomics workflow combining laser ablation ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
As monkey prices peaked in 2022, Joinn spent about 1.8 billion yuan to acquire two laboratory monkey companies and built its ...
Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment by combining the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. However, the unique ...
Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...
COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...
PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series A ...
OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...
Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled ...
Recent clinical developments in the treatment of platinum-resistant ovarian cancer (PROC) have introduced several novel therapeutic classes, including selective glucocorticoid receptor antagonists, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results